Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas K Le

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Journal of the American Academy of Dermatology|May 31, 2021
Health-related quality of life and economic burden of prurigo nodularisKatherine A Whang, Thomas K Le, Raveena Khanna, et al.
JAMA Dermatology|January 12, 2022
Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 TherapyKimberly Tang, Jayhyun Seo, Bruce C Tiu, et al.
The Journal of Investigative Dermatology|May 23, 2022
Cutaneous Toxicities Associated with Immune Checkpoint Inhibitors: An Observational, Pharmacovigilance StudyThomas K Le, Isabelle Brown, Rebecca Goldberg, et al.
Journal of the American Academy of Dermatology|February 24, 2023
Influence of melanoma type on incidence and downstream implications of cutaneous immune-related adverse events in the setting of immune checkpoint inhibitor therapyNga Nguyen, Guihong Wan, Pearl Ugwu-Dike, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Journal of the American Academy of Dermatology|May 31, 2021
Health-related quality of life and economic burden of prurigo nodularisKatherine A Whang, Thomas K Le, Raveena Khanna, et al.
JAMA Dermatology|January 12, 2022
Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 TherapyKimberly Tang, Jayhyun Seo, Bruce C Tiu, et al.
The Journal of Investigative Dermatology|May 23, 2022
Cutaneous Toxicities Associated with Immune Checkpoint Inhibitors: An Observational, Pharmacovigilance StudyThomas K Le, Isabelle Brown, Rebecca Goldberg, et al.
Journal of the American Academy of Dermatology|February 24, 2023
Influence of melanoma type on incidence and downstream implications of cutaneous immune-related adverse events in the setting of immune checkpoint inhibitor therapyNga Nguyen, Guihong Wan, Pearl Ugwu-Dike, et al.
Pageof 2